• 20954 Citations
1988 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

2020

Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors

Isakoff, S. J., Tabernero, J., Molife, L. R., Soria, J. C., Cervantes, A., Vogelzang, N. J., Patel, M. R., Hussain, M., Baron, A., Argilés, G., Conkling, P. R., Sampath, D., Maslyar, D., Patel, P., Chan, W., Gendreau, S., Musib, L., Xu, N., Ma, H., Lin, K. & 1 others, Bendell, J., May 2020, In : Annals of Oncology. 31, 5, p. 626-633 8 p.

Research output: Contribution to journalArticle

Open Access
1 Scopus citations

A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer

Sternberg, C. N., Saad, F., Graff, J. N., Peer, A., Vaishampayan, U. N., Leung, E., Rosenbaum, E., Gurney, H., Epstein, R. J., Davis, I. D., Wu, B., Trandafir, L., Wagner, V. J. & Hussain, M., Feb 2020, In : Annals of Oncology. 31, 2, p. 257-265 9 p.

Research output: Contribution to journalArticle

Open Access
1 Scopus citations

Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: U.S. Food and Drug Administration Oncology Center of Excellence Public Workshop

Weinstock, C., Suzman, D., Kluetz, P., Baxley, J., Viviano, C., Ibrahim, A., Jarow, J., Sridhara, R., Liu, K., Carroll, P., Eggener, S., Hu, J. C., Hussain, M., King, M., Klein, E., Kungel, T., Makarov, D., Pinto, P. A., Rini, B., Roach, M. & 6 others, Sandler, H., Schlegel, P. N., Song, D., Goldberg, K., Pazdur, R. & Beaver, J. A., Jan 1 2020, In : The Journal of urology. 203, 1, p. 115-119 5 p.

Research output: Contribution to journalArticle

2 Scopus citations

Efficacy and Effect of Cabozantinib on Bone Metastases in Treatment-naive Castration-resistant Prostate Cancer

Smith, D. C., Daignault-Newton, S., Grivas, P., Reichert, Z. R., Hussain, M., Cooney, K. A., Caram, M., Alva, A., Jacobson, J., Yablon, C., Mehra, R., Escara-Wilke, J., Shelley, G. & Keller, E. T., Aug 2020, In : Clinical Genitourinary Cancer. 18, 4, p. 332-339.e2

Research output: Contribution to journalArticle

1 Scopus citations

Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer

Sternberg, C. N., Fizazi, K., Saad, F., Shore, N. D., de Giorgi, U., Penson, D. F., Ferreira, U., Efstathiou, E., Madziarska, K., Kolinsky, M. P., Cubero, D. I. G., Noerby, B., Zohren, F., Lin, X., Modelska, K., Sugg, J., Steinberg, J. & Hussain, M., Jun 4 2020, In : New England Journal of Medicine. 382, 23, p. 2197-2206 10 p.

Research output: Contribution to journalArticle

9 Scopus citations

Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019[Formula presented]

Gillessen, S., Attard, G., Beer, T. M., Beltran, H., Bjartell, A., Bossi, A., Briganti, A., Bristow, R. G., Chi, K. N., Clarke, N., Davis, I. D., de Bono, J., Drake, C. G., Duran, I., Eeles, R., Efstathiou, E., Evans, C. P., Fanti, S., Feng, F. Y., Fizazi, K. & 52 others, Frydenberg, M., Gleave, M., Halabi, S., Heidenreich, A., Heinrich, D., Higano, C. T. S., Hofman, M. S., Hussain, M., James, N., Kanesvaran, R., Kantoff, P., Khauli, R. B., Leibowitz, R., Logothetis, C., Maluf, F., Millman, R., Morgans, A. K., Morris, M. J., Mottet, N., Mrabti, H., Murphy, D. G., Murthy, V., Oh, W. K., Ost, P., O'Sullivan, J. M., Padhani, A. R., Parker, C., Poon, D. M. C., Pritchard, C. C., Reiter, R. E., Roach, M., Rubin, M., Ryan, C. J., Saad, F., Sade, J. P., Sartor, O., Scher, H. I., Shore, N., Small, E., Smith, M., Soule, H., Sternberg, C. N., Steuber, T., Suzuki, H., Sweeney, C., Sydes, M. R., Taplin, M. E., Tombal, B., Türkeri, L., van Oort, I., Zapatero, A. & Omlin, A., Apr 2020, In : European urology. 77, 4, p. 508-547 40 p.

Research output: Contribution to journalArticle

Open Access
22 Scopus citations

Olaparib for metastatic castration-resistant prostate cancer

De Bono, J., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., Thiery-Vuillemin, A., Twardowski, P., Mehra, N., Goessl, C., Kang, J., Burgents, J., Wu, W., Kohlmann, A., Adelman, C. A. & Hussain, M., May 28 2020, In : New England Journal of Medicine. 382, 22, p. 2091-2102 12 p.

Research output: Contribution to journalArticle

27 Scopus citations

Olaparib for Metastatic Castration-Resistant Prostate Cancer. Reply

de Bono, J., Kang, J. & Hussain, M., Aug 27 2020, In : The New England journal of medicine. 383, 9, p. 891 1 p.

Research output: Contribution to journalLetter

Relugolix: Early Promise for a Novel Oral Androgen Deprivation Therapy with Radiation Therapy for Prostate Cancer

Sachdev, S., Zhang, H. & Hussain, M., Jan 1 2020, (Accepted/In press) In : European urology.

Research output: Contribution to journalEditorial

Survival outcomes and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer

Wong, R. L., Duong, M. T., Tangen, C. M., Agarwal, N., Cheng, H. H., Vogelzang, N. J., Hussain, M., Thompson, I. M., Quinn, D. I. & Yu, E. Y., Sep 1 2020, In : Prostate Cancer and Prostatic Diseases. 23, 3, p. 486-493 8 p.

Research output: Contribution to journalArticle

CDK12-altered prostate cancer: Clinical features and therapeutic outcomes to standard systemic therapies, poly (ADP-ribose) polymerase inhibitors, and PD-1 inhibitors

Antonarakis, E. S., Velho, P. I., Fu, W., Wang, H., Agarwal, N., Santos, V. S., Maughan, B. L., Pili, R., Adra, N., Sternberg, C. N., Vlachostergios, P. J., Tagawa, S. T., Bryce, A. H., McNatty, A. L., Reichert, Z. R., Dreicer, R., Sartor, O., Lotan, T. L. & Hussain, M., 2019, In : JCO Precision Oncology. 3, p. 370-381 12 p.

Research output: Contribution to journalArticle

7 Scopus citations

EPHB4 inhibition activates ER stress to promote immunogenic cell death of prostate cancer cells

Sagar, V., Vatapalli, R., Lysy, B., Pamarthy, S., Anker, J. F., Rodriguez, Y., Han, H., Unno, K., Stadler, W. M., Catalona, W. J., Hussain, M., Gill, P. S. & Abdulkadir, S. A., Nov 1 2019, In : Cell Death and Disease. 10, 11, 801.

Research output: Contribution to journalArticle

Open Access
8 Scopus citations

Erratum: Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 (Annals of Oncology (2015) 26(8) (1589–1604), (S0923753419318691), (10.1093/annonc/mdv257))

Gillessen, S., Omlin, A., Attard, G., de Bono, J. S., Efstathiou, E., Fizazi, K., Halabi, S., Nelson, P. S., Sartor, O., Smith, M. R., Soule, H. R., Akaza, H., Beer, T. M., Beltran, H., Chinnaiyan, A. M., Daugaard, G., Davis, I. D., De Santis, M., Drake, C. G., Eeles, R. A. & 24 others, Fanti, S., Gleave, M. E., Heidenreich, A., Hussain, M., James, N. D., Lecouvet, F. E., Logothetis, C. J., Mastris, K., Nilsson, S., Oh, W. K., Olmos, D., Padhani, A. R., Parker, C., Rubin, M. A., Schalken, J. A., Scher, H. I., Sella, A., Shore, N. D., Small, E. J., Sternberg, C. N., Suzuki, H., Sweeney, C. J., Tannock, I. F. & Tombal, B., Dec 2019, In : Annals of Oncology. 30, 12, p. e3

Research output: Contribution to journalComment/debate

Open Access
5 Scopus citations

Inflammatory Bowel Disease and the Risk of Prostate Cancer

Burns, J. A., Weiner, A. B., Catalona, W. J., Li, E. V., Schaeffer, E. M., Hanauer, S. B., Strong, S., Burns, J., Hussain, M. H. A. & Kundu, S. D., May 2019, In : European urology. 75, 5, p. 846-852 7 p.

Research output: Contribution to journalArticle

12 Scopus citations

Metastatic hormone-sensitive prostate cancer: Clinical decision making in a rapidly evolving landscape of life-prolonging therapy

VanderWeele, D. J., Antonarakis, E. S., Carducci, M. A., Dreicer, R., Fizazi, K., Gillessen, S., Higano, C. S., Morgans, A. K., Petrylak, D. P., Sweeney, C. J. & Hussain, M., Jan 1 2019, In : Journal of Clinical Oncology. 37, 32, p. 2961-2967 7 p.

Research output: Contribution to journalComment/debate

2 Scopus citations

Olaparib to change practice in mCRPC

Hussain, M., Dec 2019, In : Cancer discovery. 9, 12, p. 1638-1639 2 p.

Research output: Contribution to journalComment/debate

Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial

Tombal, B., Saad, F., Penson, D., Hussain, M., Sternberg, C. N., Morlock, R., Ramaswamy, K., Ivanescu, C. & Attard, G., Apr 2019, In : The Lancet Oncology. 20, 4, p. 556-569 14 p.

Research output: Contribution to journalArticle

24 Scopus citations

Revisiting Intermittent Therapy in Metastatic Prostate Cancer: Can Less Be More in the “New World Order”?

Shevach, J., Sydes, M. R. & Hussain, M., Mar 2019, In : European Urology Focus. 5, 2, p. 125-133 9 p.

Research output: Contribution to journalReview article

3 Scopus citations
2018

Acquired resistance to poly (ADP-ribose) polymerase inhibitor olaparib in BRCA2-associated prostate cancer resulting from biallelic BRCA2 reversion mutations restores both germline and somatic loss-of-function mutations

Carneiro, B. A., Collier, K. A., Nagy, R. J., Pamarthy, S., Sagar, V., Fairclough, S., Odegaard, J., Lanman, R. B., Costa, R., Taxter, T., Kuzel, T. M., Fan, A., Chae, Y. K., Cristofanilli, M., Hussain, M. H., Abdulkadir, S. A. & Giles, F. J., Jan 1 2018, In : JCO Precision Oncology. 2

Research output: Contribution to journalArticle

15 Scopus citations

A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic (M0) castration-resistant prostate cancer (CRPC): Results of PROSPER by age and region

Fizazi, K., Hussain, M., Saad, F., Shore, N., De Giorgi, U., Efstathiou, E., Ferreira, U., Ivashchenko, P., Madziarska, K., Al-Adhami, M., Modelska, K., Phung, D., Steinberg, J. & Sternberg, C. N., Oct 1 2018, In : Annals of oncology : official journal of the European Society for Medical Oncology. 29, p. viii277-viii278

Research output: Contribution to journalArticle

Open Access

Bone metabolism biomarkers (BMB) in hormone sensitive prostate cancer (HSPC): Results from SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) +/- orteronel

Lara, P. N., Mayerson, E., Gertz, E., Tangen, C., Goldkorn, A., van Loan, M., Hussain, M., Gupta, S., Zhang, J., Twardowski, P., Quinn, D. I., Vogelzang, N. J., Thompson, I. & Agarwal, N., Oct 1 2018, In : Annals of oncology : official journal of the European Society for Medical Oncology. 29, p. viii275-viii276

Research output: Contribution to journalArticle

Open Access

Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421

Lara, P. N., Plets, M., Tangen, C., Gertz, E., Vogelzang, N. J., Hussain, M., Twardowski, P. W., Garzotto, M. G., Monk, J. P., Carducci, M., Goldkorn, A., Mack, P. C., Thompson, I., Van Loan, M. & Quinn, D. I., Jan 1 2018, In : Cancer Treatment and Research Communications. 16, p. 18-23 6 p.

Research output: Contribution to journalArticle

1 Scopus citations

Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies

Gravis, G., Boher, J. M., Chen, Y. H., Liu, G., Fizazi, K., Carducci, M. A., Oudard, S., Joly, F., Jarrard, D. M., Soulie, M., Eisenberger, M. J., Habibian, M., Dreicer, R., Garcia, J. A., Hussain, M. H. M., Kohli, M., Vogelzang, N. J., Picus, J., DiPaola, R. & Sweeney, C., Jun 2018, In : European urology. 73, 6, p. 847-855 9 p.

Research output: Contribution to journalArticle

63 Scopus citations

Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 chaarted trial

Kyriakopoulos, C. E., Chen, Y. H., Carducci, M. A., Liu, G., Jarrard, D. F., Hahn, N. M., Shevrin, D. H., Dreicer, R., Hussain, M., Eisenberger, M., Kohli, M., Plimack, E. R., Vogelzang, N. J., Picus, J., Cooney, M. M., Garcia, J. A., DiPaola, R. S. & Sweeney, C. J., Apr 10 2018, In : Journal of Clinical Oncology. 36, 11, p. 1080-1087 8 p.

Research output: Contribution to journalArticle

173 Scopus citations

Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer

Cheng, H. H., Plets, M., Li, H., Higano, C. S., Tangen, C. M., Agarwal, N., Vogelzang, N. J., Hussain, M., Thompson, I. M., Tewari, M. & Yu, E. Y., Feb 1 2018, In : Prostate. 78, 2, p. 121-127 7 p.

Research output: Contribution to journalArticle

3 Scopus citations

Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer

Hussain, M., Fizazi, K., Saad, F., Rathenborg, P., Shore, N., Ferreira, U., Ivashchenko, P., Demirhan, E., Modelska, K., Phung, D., Krivoshik, A. & Sternberg, C. N., Jun 28 2018, In : New England Journal of Medicine. 378, 26, p. 2465-2474 10 p.

Research output: Contribution to journalArticle

276 Scopus citations

MAPK Reliance via acquired CDK4/6 inhibitor resistance in cancer

De Leeuw, R., McNair, C., Schiewer, M. J., Neupane, N. P., Brand, L. J., Augello, M. A., Li, Z., Cheng, L. C., Yoshida, A., Courtney, S. M., Starr Hazard, E., Hardiman, G., Hussain, M. H., Alan Diehl, J., Drake, J. M., Kevin Kelly, W. & Knudsen, K. E., Sep 1 2018, In : Clinical Cancer Research. 24, 17, p. 4201-4214 14 p.

Research output: Contribution to journalArticle

18 Scopus citations

Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and atrasentan versus docetaxel and placebo in a randomized phase iii clinical trial (Swog s0421)

Unger, J. M., Griffin, K., Donaldson, G. W., Baranowski, K. M., Good, M. J., Reburiano, E., Hussain, M., Monk, P. J., Van Veldhuizen, P. J., Carducci, M. A., Higano, C. S., Lara, P. N., Tangen, C. M., Quinn, D. I., Wade, J. L., Vogelzang, N. J., Thompson, I. M. & Moinpour, C. M., 2018, In : Journal of Patient-Reported Outcomes. 2, 27.

Research output: Contribution to journalArticle

Open Access
4 Scopus citations

Phase III intergroup trial of adjuvant androgen deprivation with or without mitoxantrone plus prednisone in patients with high-risk prostate cancer after radical prostatectomy: SWOG S9921

Hussain, M., Tangen, C. M., Thompson, I. M., Swanson, G. P., Wood, D. P., Sakr, W., Dawson, N. A., Haas, N. B., Flaig, T. W., Dorff, T. B., Lin, D. W., David Crawford, E., Quinn, D. I., Vogelzang, N. J. & Michael Glode, L., May 20 2018, In : Journal of Clinical Oncology. 36, 15, p. 1498-1504 7 p.

Research output: Contribution to journalArticle

13 Scopus citations

Prolonged urinary and bowel symptom control in men with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with enzalutamide: Results from the PROSPER study

Tombal, B., Hussain, M., Penson, D., Attard, G., Sternberg, C. N., Phung, D., Morlock, R., Modelska, K., Ramaswamy, K., Ivanescu, C. & Saad, F., Oct 1 2018, In : Annals of oncology : official journal of the European Society for Medical Oncology. 29, p. viii278-viii279

Research output: Contribution to journalArticle

Open Access

Prostate cancer screening and the goldilocks principle: How much is just right?

Faiena, I., Holden, S., Cooperberg, M. R., Holden, S., Soule, H. R., Simons, J. W., Morgan, T. M., Penson, D. F., Morgans, A. K. & Hussain, M., 2018, In : Journal of Clinical Oncology. 36, 10, p. 937-941 5 p.

Research output: Contribution to journalComment/debate

3 Scopus citations

Quality of life during treatment with chemohormonal therapy: Analysis of E3805 chemohormonal androgen ablation randomized trial in prostate cancer

Morgans, A. K., Chen, Y. H., Sweeney, C. J., Jarrard, D. F., Plimack, E. R., Gartrell, B. A., Carducci, M. A., Hussain, M., Garcia, J. A., Cella, D., DiPaola, R. S. & Patrick-Miller, L. J., Apr 10 2018, In : Journal of Clinical Oncology. 36, 11, p. 1088-1095 8 p.

Research output: Contribution to journalArticle

25 Scopus citations

Seven-month prostate-specific antigen is prognostic in metastatic hormone-sensitive prostate cancer treated with androgen deprivation with or without docetaxel

Harshman, L. C., Chen, Y. H., Liu, G., Carducci, M. A., Jarrard, D., Dreicer, R., Hahn, N., Garcia, J. A., Hussain, M., Shevrin, D., Eisenberger, M., Kohli, M., Plimack, E. R., Cooney, M., Vogelzang, N. J., Picus, J., Dipaola, R. & Sweeney, C. J., Feb 1 2018, In : Journal of Clinical Oncology. 36, 4, p. 376-382 7 p.

Research output: Contribution to journalArticle

23 Scopus citations

Targeting androgen receptor and DNA repair in metastatic castration-resistant prostate cancer: Results from NCI 9012

Hussain, M., Daignault-Newton, S., Twardowski, P. W., Albany, C., Stein, M. N., Kunju, L. P., Siddiqui, J., Wu, Y. M., Robinson, D., Lonigro, R. J., Cao, X., Tomlins, S. A., Mehra, R., Cooney, K. A., Montgomery, B., Antonarakis, E. S., Shevrin, D. H., Corn, P. G., Whang, Y. E., Smith, D. C. & 5 others, Caram, M. V., Knudsen, K. E., Stadler, W. M., Feng, F. Y. & Chinnaiyan, A. M., Apr 1 2018, In : Journal of Clinical Oncology. 36, 10, p. 991-999 9 p.

Research output: Contribution to journalArticle

64 Scopus citations
2017

Abiraterone acetate for metastatic prostate cancer in patients with suboptimal biochemical response to hormone induction

Flaig, T. W., Plets, M., Hussain, M. H. A., Agarwal, N., Mitsiades, N., Deshpande, H. A., Vaishampayan, U. N. & Thompson, I. M., Nov 2017, In : JAMA Oncology. 3, 11, e170231.

Research output: Contribution to journalArticle

6 Scopus citations

Precision, complexity and stigma in advanced prostate cancer terminology: It is time to move away from 'castration-resistant' prostate cancer

ANZUP Consumer Advisory Panel, Aug 1 2017, In : Annals of Oncology. 28, 8, p. 1692-1694 3 p.

Research output: Contribution to journalEditorial

4 Scopus citations

Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy

Hovelson, D. H., Liu, C. J., Wang, Y., Kang, Q., Henderson, J., Gursky, A., Brockman, S., Ramnath, N., Krauss, J. C., Talpaz, M., Kandarpa, M., Chugh, R., Tuck, M., Herman, K., Grasso, C. S., Quist, M. J., Feng, F. Y., Haakenson, C., Langmore, J., Kamberov, E. & 12 others, Tesmer, T., Husain, H., Lonigro, R. J., Robinson, D., Smith, D. C., Alva, A. S., Hussain, M. H., Chinnaiyan, A. M., Tewari, M., Mills, R. E., Morgan, T. M. & Tomlins, S. A., 2017, In : Oncotarget. 8, 52, p. 89848-89866 19 p.

Research output: Contribution to journalArticle

23 Scopus citations

Risk stratification in oligometastatic prostate cancer: Where are we and what do we need?

Morgans, A. K. & Hussain, M., Nov 1 2017, In : Current Opinion in Urology. 27, 6, p. 547-552 6 p.

Research output: Contribution to journalReview article

1 Scopus citations

The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies

Rimar, K. J., Tran, P. T., Matulewicz, R. S., Hussain, M. & Meeks, J. J., Jun 1 2017, In : Cancer. 123, 11, p. 1912-1924 13 p.

Research output: Contribution to journalReview article

19 Scopus citations

The role of genomics in patients with advanced prostate cancer

Hussain, M. H., Oct 2017, In : Clinical Advances in Hematology and Oncology. 15, 10, p. 770-772 3 p.

Research output: Contribution to journalComment/debate

1 Scopus citations

Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421

Sonpavde, G., Pond, G. R., Plets, M., Tangen, C. M., Hussain, M. H. A., Lara, P. N., Goldkorn, A., Garzotto, M. G., Mack, P. C., Higano, C. S., Vogelzang, N. J., Thompson, I. M., Twardowski, P. W., Van Veldhuizen, P. J., Agarwal, N., Carducci, M. A., Monk, J. P. & Quinn, D. I., Dec 2017, In : Clinical Genitourinary Cancer. 15, 6, p. 635-641 7 p.

Research output: Contribution to journalArticle

2 Scopus citations
2016

ADAM15 is functionally associated with the metastatic progression of human bladder cancer

Hiles, G. L., Bucheit, A., Rubin, J. R., Hayward, A., Cates, A. L., Day, K. C., El-Sawy, L., Kunju, L. P., Daignault, S., Lee, C. T., Liebert, M., Hussain, M. & Day, M. L., Mar 2016, In : PloS one. 11, 3, e0150138.

Research output: Contribution to journalArticle

10 Scopus citations

Adverse health events following intermittent and continuous androgen deprivation in patients with metastatic prostate cancer

Hershman, D. L., Unger, J. M., Wright, J. D., Ramsey, S., Till, C., Tangen, C. M., Barlow, W. E., Blanke, C., Thompson, I. M. & Hussain, M., Apr 2016, In : JAMA Oncology. 2, 4, p. 453-461 9 p.

Research output: Contribution to journalArticle

57 Scopus citations

Androgen receptor and beyond, targeting androgen signaling in castration-resistant prostate cancer

Reichert, Z. R. & Hussain, M., Sep 1 2016, In : Cancer Journal (United States). 22, 5, p. 326-329 4 p.

Research output: Contribution to journalReview article

5 Scopus citations

A phase 2 trial of salvage radiation and concurrent weekly docetaxel after a rising prostate-specific antigen level after radical prostatectomy

Jackson, W. C., Feng, F. Y., Daignault, S., Hussain, M., Smith, D., Cooney, K., Pienta, K., Jolly, S., Hollenbeck, B., Olson, K. B., Sandler, H. M., Ray, M. E. & Hamstra, D. A., Jan 1 2016, In : Advances in Radiation Oncology. 1, 1, p. 59-66 8 p.

Research output: Contribution to journalArticle

A Phase II Study of AT-101 to Overcome Bcl-2-Mediated Resistance to Androgen Deprivation Therapy in Patients with Newly Diagnosed Castration-Sensitive Metastatic Prostate Cancer

Stein, M. N., Hussain, M., Stadler, W. M., Liu, G., Tereshchenko, I. V., Goodin, S., Jeyamohan, C., Kaufman, H. L., Mehnert, J. & Dipaola, R. S., Feb 1 2016, In : Clinical Genitourinary Cancer. 14, 1, p. 22-27 6 p.

Research output: Contribution to journalArticle

17 Scopus citations

Differential effect on bone lesions of targeting integrins: Randomized phase II trial of abituzumab in patients with metastatic castration-resistant prostate cancer

Hussain, M., Le Moulec, S., Gimmi, C., Bruns, R., Straub, J., Miller, K. & PERSEUS Study Group, Jul 1 2016, In : Clinical Cancer Research. 22, 13, p. 3192-3200 9 p.

Research output: Contribution to journalArticle

21 Scopus citations

Evaluating intermittent androgen-deprivation therapy phase III clinical trials: The devil is in the details

Hussain, M., Tangen, C., Higano, C., Vogelzang, N. & Thompson, I., Jan 20 2016, In : Journal of Clinical Oncology. 34, 3, p. 280-285 6 p.

Research output: Contribution to journalArticle

22 Scopus citations